Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...

The blue-chip Dow Jones Industrial Average closed at a record high as a subdued inflation report stoked hopes for more ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

Studies showed Bristol Myers Squibb's drug, KarXT, improved symptoms of schizophrenia and led to fewer side effects than existing antipsychotic treatments. Researchers are optimistic patients might ...

U.S. stocks closed another record-setting week with a muted performance Friday, as hope built on Wall Street that the U.S. economy can manage the rare feat of suppressing high inflation without ...

The Dow Jones Industrial Average reached a record high following a modest inflation report, spurring hopes for additional ...

The blue-chip Dow Jones Industrial Average closed at a record high today as investors welcomed a subdued inflation report ...

The Dow Jones Industrial Average edged up to another record high while declines in tech stocks pulled other indexes lower.

In a breakthrough for people with schizophrenia, the FDA has approved a new oral medication for adults. Unlike traditional antipsychotic drugs, the medication, which will be marketed under the name ...

The Dow Jones Industrial Average closed at a record high, driven by investor optimism following a subdued inflation report.

Bristol Myers Squibb (BMY) is up more than +1% after gaining FDA approval for its Cobenfy drug to treat patients with schizophrenia. Amgen (AMGN) is up more than +1% after Cantor Fitzgerald initiated ...